Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.54 USD
-0.13 (-7.78%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $1.52 -0.02 (-1.30%) 4:18 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Iterum Therapeutics PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -38.37 | -44.43 | -91.56 | -52.01 | -103.13 |
Depreciation/Amortization & Depletion | 4.09 | 4.14 | 6.20 | 11.09 | 0.51 |
Net Change from Assets/Liabilities | 2.76 | 2.31 | -0.44 | -24.56 | 17.90 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -7.81 | 19.51 | 69.96 | 10.94 | 5.83 |
Net Cash From Operating Activities | -39.33 | -18.47 | -15.84 | -54.53 | -78.89 |
Property & Equipment | -0.01 | -0.06 | -0.06 | -0.01 | -0.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 23.35 | 14.02 | -54.53 | 0.00 | 40.13 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 23.34 | 13.96 | -54.60 | -0.01 | 40.10 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.03 | 0.43 | 89.64 | 24.93 | 0.06 |
Issuance (Repayment) of Debt | 0.00 | -2.25 | -6.52 | -5.49 | -1.03 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 45.04 | 0.00 |
Net Cash from Financing Activities | 1.03 | -1.82 | 83.13 | 64.48 | -0.97 |
Effect of Exchange Rate Changes | -0.06 | -0.05 | 0.00 | -0.01 | -0.02 |
Net Change In Cash & Equivalents | -15.02 | -6.38 | 12.69 | 9.93 | -39.78 |
Cash at Beginning of Period | 21.13 | 27.51 | 14.82 | 4.89 | 44.67 |
Cash at End of Period | 6.11 | 21.13 | 27.51 | 14.82 | 4.89 |
Diluted Net EPS | -2.96 | -3.63 | -8.40 | -32.53 | -106.45 |
Fiscal Year End for Iterum Therapeutics PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -38.37 | -26.01 | -22.13 | -9.89 |
Depreciation/Amortization & Depletion | NA | 4.09 | 3.06 | 2.04 | 1.01 |
Net Change from Assets/Liabilities | NA | 2.76 | 5.06 | -0.88 | -2.72 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | -7.81 | -8.60 | 3.75 | 2.01 |
Net Cash From Operating Activities | NA | -39.33 | -26.49 | -17.22 | -9.59 |
Property & Equipment | NA | -0.01 | -0.01 | -0.02 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 23.35 | 9.83 | 9.47 | 5.11 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 23.34 | 9.81 | 9.45 | 5.11 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.03 | 0.45 | 0.44 | 0.24 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 1.03 | 0.45 | 0.44 | 0.24 |
Effect of Exchange Rate Changes | NA | -0.06 | -0.05 | -0.02 | -0.01 |
Net Change In Cash & Equivalents | NA | -15.02 | -16.28 | -7.36 | -4.26 |
Cash at Beginning of Period | NA | 21.13 | 21.13 | 21.13 | 21.13 |
Cash at End of Period | NA | 6.11 | 4.85 | 13.77 | 16.87 |
Diluted Net EPS | NA | -0.93 | -0.30 | -0.95 | -0.78 |